The Austrian biotech company is benefiting from the increased demand for virus blockers.
According to preliminary figures, the listed Austrian biotech company Marinomed increased its sales in the previous year by 33 percent to 8.1 million euros, but ended the 2020 financial year with a loss, as previously announced.
Special items
Compared to the previous year's sales adjusted for special effects from a license agreement, the sales increase was 55 percent, the company announced on Friday.
Marinomed produces, among other things, a nasal spray against viral respiratory infections, which should also be effective as a virus blocker. “Of course, the pandemic requires additional expenditure of time and resources in some of our activities,” said Marinomed boss Andreas Grassauer, according to the announcement.
Well on schedule
“Our development and clinical program for Marinosolv as well as the two clinical phase IV studies examining the potential of carragelose in the prevention and therapy of Covid-19 are well on schedule.”
